Abstract
Antioxidant status determines the susceptibility of tissues to the oxidative stress associated with diabetes and its complications; hence in the present study antioxidant status was explored in streptozotocin-induced diabetic rats treated with vanadium in the form of vanadium pentoxide nanoparticles. Vanadium pentoxide and vanadium pentoxide nanoparticles at the dose rate of 5mg/kg were administered orally in STZ (50mg/Kg) induced diabetic rats for 30 days and glimepiride (reference drug) was administered orally at the dose rate of 800 ìg/kg body weight. Vanadium pentoxide nanoparticles significantly reduced the blood glucose levels than the diabetic control and other treatment group of rats. On exploration of antioxidant status in liver, kidney and pancreas tissues, vanadium in the form of vanadium pentoxide nanoparticles outperformed the vanadium pentoxide by increasing the activities of the enzymes catalase, superoxide dismutase and glutathione peroxidase, and the concentration of reduced glutathione and by decreasing the lipid peroxide levels. The present study also showed that the restoration of antioxidant status by vanadium pentoxide nanoparticles is comparable with that of the reference drug. It can be concluded that vanadium pentoxide nanoparticles, due to its superior control over hyperglycemia and antioxidant properties, outperformed the vanadium pentoxide treatment in enhancing the antioxidant status in diabetic rats.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
